|
|||||
|
|
A comparison of HMGB1 concentrations between cerebrospinal fluid and blood in patients with neurological disease |
|
| Authors: | Lauren Elizabeth Walker Michael John Griffiths Fiona McGill Penelope Lewthwaite Graeme John Sills Andrea Jorgensen |
| Institution: | 1. Department of Molecular and Clinical Pharmacology, Institute of Translational Medicine University of Liverpool, Liverpool, United Kingdom;2. Department of Clinical Infection, Microbiology and Immunology, Institute of Infection and Global Health UK, University of Liverpool, Liverpool, United Kingdom;3. NIHR Health Protection Research Unit in Emerging and Zoonotic Infections, University of Liverpool, Liverpool, United Kingdom;4. Department of Infectious Diseases, Leeds Teaching Hospitals NHS Trust, West Yorkshire, Leeds, United Kingdom |
| Abstract: | Aims: To determine whether a correlation exists between paired cerebrospinal fluid (CSF) and serum levels of a novel inflammatory biomarker, high-mobility group box 1 (HMGB1), in different neurological conditions. Methods: HMGB1 was measured in the serum and CSF of 46 neurological patients (18 idiopathic intracranial hypertension IIH], 18 neurological infection/inflammation NII] and 10 Rasmussen’s encephalitis RE]). Results: Mean serum (±?SD) HMGB1 levels were 1.43?±?0.54, 25.28?±?27.9 and 1.89?±?1.49?ng/ml for the patients with IIH, NII and RE, respectively. Corresponding mean (±?SD) CSF levels were 0.35?±?0.22, 4.48?±?6.56 and 2.24?±?2.35?ng/ml. Both CSF and serum HMGB1 was elevated in NII. Elevated CSF HMGB1 was demonstrated in RE. There was no direct correlation between CSF and serum levels of HMGB1. Conclusion: Serum HMGB1 cannot be used as a surrogate measure for CSF levels. CSF HMGB1 was elevated in NII and RE, its role as a prognostic/stratification biomarker needs further study. |
| Keywords: | High-mobility group box 1 (HMGB1) biomarker cerebrospinal fluid |